← All organizations

US WorldMeds

For profitContributed to NME

Also known as: USWM | USWM, LLC (dba US WorldMeds) | US WorldMeds | US WORLDMEDS | US WorldMeds LLC | US WORLDMEDS LLC | US WorldMeds Medical Monitor

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 4

First clinical trial

First marketed drug

First NDA

Last known activity

Jan 31, 2025

Timeline

1970s

Dec 10, 1979
nadolol— NDA Secondary Org

2000s

Jul 1, 2001
US WorldMeds— Founded

2010s

Jan 1, 2010
Solstice Neurosciences— Acquired
May 16, 2018
lofexidine— NDA Organization
May 3, 2019
melphalan— Marketing Organization

Drugs by trial phase (8 distinct, 32 trials)

Phase 4 (4 own, 1 via acquisition)

Phase 1 (3 own, 0 via acquisition)

Indications

Approved for

Opioid-Related Disorders

Studied for

Marketed drugs (8)

Subsidiaries (1 direct, 1 total across the full acquisition tree)

Solstice Neurosciences

Recent trials (44)

NCT06711640Lead sponsorPhase 1Jan 31, 2025
NCT06047834Lead sponsorPhase 2Oct 2, 2023
NCT04360681CollaboratorPhase 2Aug 28, 2020
NCT04188730Study chairPhase 1Jan 31, 2020
NCT04188730Lead sponsorPhase 1Jan 31, 2020
NCT04099667Study directorPhase 2/Phase 3Oct 31, 2019
NCT04099667Lead sponsorPhase 2/Phase 3Oct 31, 2019
NCT04056182CollaboratorPhase 2Sep 1, 2019
NCT04126083CollaboratorPhase 4Sep 1, 2019
NCT04070157Lead sponsorPhase 2Aug 2, 2019
NCT04070157Study directorPhase 2Aug 2, 2019
NCT02801357Lead sponsorPhase 1Jun 1, 2016
NCT02681198Lead sponsorPhase 1Feb 1, 2016
NCT02549573Lead sponsorPhase 4Jan 1, 2016
NCT02549573Study directorPhase 4Jan 1, 2016

Details

Founded: Louisville, KY, US Jul 1, 2001
First NDA: May 16, 2018
Last known activity: Jan 31, 2025

Designations held

Fast track
Priority review

Notes

acquired Solstice Neurosciences - 13 Aug 2010